• English
  • Korean
  • Chinese
表紙
市場調査レポート - 170803

様々な疾患のための早期創薬:幹細胞療法および遺伝子療法を中心とした技術革新

Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies

発行 GBI Research
出版日 ページ情報 英文 209 Pages
電子版即納可
価格
様々な疾患のための早期創薬:幹細胞療法および遺伝子療法を中心とした技術革新 Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
出版日: 2011年02月10日 ページ情報: 英文 209 Pages
概要

早期創薬には創薬および前臨床試験段階の開発中の薬剤を含みます。薬剤の安全性と有効性を評価するために実施されるもので、各企業が開発を進めるべき分子を判断するという点で、薬剤開発の中でも重要な役割を担います。FDAが出したリスクアセスメント戦略といった様々な戦略が創薬の早期段階で安全性を精査する取り組みが行なわれています。

当レポートでは、様々な疾患のための早期創薬研究動向について分析し、現状と製薬会社にとっての課題、主な治療セグメント、参入する大手企業5社のプロファイル、戦略的考察などを交え、概略以下の構成でお届けします。

第1章 目次

第2章 早期創薬:イントロダクション

第3章 概要

  • 創薬と新薬開発
  • 早期創薬研究:概要
  • 早期創薬デザインとプランニング

第4章 技術環境

  • 現在のシステム
  • 技術モデルの動向

第5章 創薬と新薬開発:製薬会社にとっての課題

  • 創薬および開発プロセス

第6章 治療セグメントにおける早期創薬

  • 中枢神経系疾患
  • 代謝性疾患
  • 免疫疾患
  • 感染症
  • 心血管疾患

第7章 早期創薬に参入する大手製薬会社5社

  • イントロダクション
  • Hanall Pharmaceutical
  • Patrys Limited
  • F. Hoffmann-La Roche Ltd
  • Mirna Therapeutics
  • Aphios Corporation

第8章 戦略的考察

  • 研究開発ライセンシング契約
    • 適応別
    • 地域別
    • 治療クラス別

第9章 付録

図表

目次

Abstract

GBI Research, the leading business intelligence provider, has released its latest research, “Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies”. It provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease and Oncology therapeutic markets. The report analyzes the early stage drug development that includes drugs under development in the discovery and preclinical stages of development for the above mentioned indications in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and the annual cost of therapy are forecast until 2017 for the key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the Mergers and Acquisitions (M&A) and licensing agreements that shape the global market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Oncology is the Key Therapeutic Segment of the Early Stage Drug Pipeline

Early stage drug development includes drugs under development in the discovery and preclinical stages of development. These studies are conducted in order to assess the safety and efficacy of the drug. This stage of development plays a key role in drug development as it determines potential molecules to be further processed for development by different companies. Increased strategies like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are persuading companies to implement safety scrutiny measures at early stages of development.

The majority of the molecules in the early stages of development are being developed for cancer indications. Molecules under development for breast cancer account for 23% of the total early stage development molecules under development for cancer. This is followed by prostate cancer, accounting for 20%, followed by colon cancer (15%).

Other than Oncology, other therapeutic areas with high activity in Research and Development (R&D) in early development phases include Central Nervous System (CNS) disorders, immunological disorders, and metabolic disorders. CNS disorders accounted for 14% of early stage drugs under development, followed by immunological disorders (13%) and metabolic disorders (10%). Compared to other therapeutic areas, there is less R&D activity in the metabolic disorders (9%) and infectious disease (9%) segments.

Breast Cancer Therapeutics Leads the Early Stage Drug Developmental Pipeline; Immunotherapy accounts for 33% of the Drug Classes Under Development

The breast cancer early stage pipeline consists of 141 molecules, with 22 molecules in the discovery phase and 119 molecules in the preclinical phase. These molecules are in development for the treatment of patients suffering with breast cancer. The discovery phase of the breast cancer pipeline consists of 16% of the molecules and the preclinical phase consists of 84% of the pipeline.

The early stage breast cancer therapeutics pipeline has been supplemented by novel therapeutic molecules. Immunotherapy, with 47 molecules, contributes 33% of the pipeline. Protein receptor targetors contribute 16%. Enzyme inhibitors contribute 12% of the pipeline. Vaccines contribute 8% of the pipeline. Gene therapy contributes 5% of the pipeline. Apoptosis targetors contribute to 3%. Chemotherapy, angiogenic antagonists, stem cell therapy and hormones with two molecules each contribute 1%. Combination therapy, with three molecules, contributes 2%. Cellular motility inhibitors, synthetic picolinic ester-substituted retinoids, microtubule inhibitors with one molecule each contribute to 1% each. Few drugs with the mechanisms of action apart from these major classes contribute to 13% of the pipeline.

Key Players in the Early Stage Drug Development Pipeline are Hanall Pharmaceutical, Patrys and F. Hoffman La Roche

In early stage drug development, as in, drugs in the discovery and preclinical phases of development, the key players were identified to be Hanall Pharmaceutical Co. Ltd, Patrys Limited, F. Hoffman La Roche, Mirna Therapeutics and Aphios Corporation. These key players showed immense activity in R&D in the early stages of drug development in different therapeutic areas like CNS, cardiovascular diseases, oncology, infection, immunological disorders and metabolic disorders. Hanall Pharmaceuticals has 39 molecules in discovery as well as preclinical stage Parkinson’s disease, diabetes, Alzheimer’s disease, hepatitis, allergy and hypertension. Patrys Limited has 19 molecules in development in the discovery and preclinical stages of development in different therapeutic segments like ovarian cancer, lung cancer and colon cancer. Roche has 17 molecules in development in the discovery and preclinical stages of development in different therapeutic segments like prostate cancer, lung cancer, melanoma, breast cancer, colon cancer, schizophrenia, obesity and Human Immunodeficiency Virus (HIV) that causes Acquired Immunodeficiency Syndrome (AIDS).

Summary

GBI Research’s new report, “Early Stage Drug Development in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies”, provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease and Oncology therapeutic markets. The report analyzes the early stage drug development that includes drugs under development in the discovery and preclinical stages of development for the above mentioned indications in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and the annual cost of therapy are forecast until 2017 for the key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the Mergers and Acquisitions (M&A) and licensing agreements that shape the global market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that early stage drug development includes drugs under development in the discovery and preclinical stages of development. These studies are conducted in order to assess the safety and efficacy of the drug. This stage of development plays a key role in drug development as it determines potential molecules to be further processed for development by different companies. Increased strategies like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are persuading companies to implement safety scrutiny measures at early stages of development.

The majority of the molecules in the early stages of development are being developed for cancer indications. Molecules under development for breast cancer account for 23% of the total early stage development molecules under development for cancer. This is followed by prostate cancer, accounting for 20%, followed by colon cancer (15%).

Other than Oncology, other therapeutic areas with high activity in Research and Development (R&D) in early development phases include Central Nervous System (CNS) disorders, immunological disorders, and metabolic disorders. CNS disorders accounted for 14% of early stage drugs under development, followed by immunological disorders (13%) and metabolic disorders (10%). Compared to other therapeutic areas, there is less R&D activity in the metabolic disorders (9%) and infectious disease (9%) segments.

Scope

The scope of this report includes -
• Coverage of pipeline molecules in various discovery and pre-clinical phases of drug development along with pipeline analysis of the leading therapeutic segments, including Oncology, CNS disorders, immunological disorders, infection, metabolic disorders and cardiovascular disorders.
• Analysis of the above mentioned disorders market in the leading geographies of the world, which are the US, the UK, Germany, France, Italy, Spain and Japan.
• Key drivers and barriers that have a significant impact on the market.
• Competitive benchmarking of leading companies. The key companies studied in this report are Hanall Pharmaceutical Co. Ltd, Patrys Limited, F. Hoffmann-La Roche Ltd, Mirna Therapeutics, Inc. and Aphios Corporation.
• Key M&A activities and licensing agreements that have taken place between 2005 and 2010 in the global Oncology, CNS disorders, immunological disorders, infection, metabolic disorders and cardiovascular disorders markets.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
• Develop key strategic initiatives by understanding the key focus areas of leading companies.
• Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Early Stage Drug Discovery in Disease Segments - Introduction

  • 2.1 GBI Research Report Guidance

3. Early Stage Drug Discovery in Disease Segments - Overview

  • 3.1 Drug Discovery and Development
    • 3.1.1 Drug Development-Stages
  • 3.2 Early Stage Drug Discovery Studies- An overview
  • 3.3 Early Stage Drug Discovery Design and Planning
    • 3.3.1 Early Stage Drug Discovery - Strategic Planning
    • 3.3.2 Key Considerations During Early Stage Drug Discovery

4. Early Stage Drug Discovery in Disease Segments - Technology Landscape

  • 4.1 Current System
    • 4.1.1 Overview
    • 4.1.2 Key Technologies
    • 4.1.3 In-vitro ADMET Screening Models
    • 4.1.4 In vivo ADMET Screening Models
    • 4.1.5 In silico ADMET Screening models
  • 4.2 Trends in Technology Models
    • 4.2.1 Recent Technology Developments

5. Early Stage Drug Discovery in Disease Segments - Drug Discovery and Development - A Challenge to Pharmaceutical Companies

  • 5.1 Drug Discovery & Development Process
    • 5.1.1 Drug Discovery Process

6. Early Stage Drug Discovery in Therapeutic Segments

  • 6.1 Central Nervous System Disorders
    • 6.1.1 Alzheimer's disease
    • 6.1.2 Parkinson's disease
    • 6.1.3 Multiple Sclerosis
    • 6.1.4 Schizophrenia
  • 6.2 Metabolic Disorders
    • 6.2.1 Diabetes
    • 6.2.2 Obesity
  • 6.3 Immunological Disorders
    • 6.3.1 Rheumatoid Arthritis
    • 6.3.2 Crohn's Disease
    • 6.3.3 Systemic Lupus Erythematosus (SLE)
    • 6.3.4 Allergy
  • 6.4 Infections
    • 6.4.1 HIV/AIDS
    • 6.4.2 Hepatitis A, B, C
  • 6.5 Cardiovascular Diseases
    • 6.5.1 Hypertension
    • 6.5.2 Dyslipidemia
    • 6.5.3 Pulmonary Arterial Hypertension (PAH)
    • 6.5.4 Myocardial Infarction
  • 6.6 Oncology
    • 6.6.1 Bladder Cancer
    • 6.6.2 Lung Cancer
    • 6.6.3 Non-Small Cell Lung Cancer (NSLC)
    • 6.6.4 Breast Cancer
    • 6.6.5 Colon Cancer
    • 6.6.6 Melanoma
    • 6.6.7 Ovarian Cancer
    • 6.6.8 Prostate Cancer

7. Early Stage Drug Discovery in Disease Segments - Top Five Pharmaceutical Players in Early Stage Drug Discovery

  • 7.1 Introduction
  • 7.2 Hanall Pharmaceutical
    • 7.2.1 Company Overview
    • 7.2.2 Pipeline
  • 7.3 Patrys Limited
    • 7.3.1 Company Overview
    • 7.3.2 Pipeline
  • 7.4 F. Hoffmann-La Roche Ltd.
    • 7.4.1 Company Overview
    • 7.4.2 Pipeline
  • 7.5 Mirna Therapeutics
    • 7.5.1 Company Overview
    • 7.5.2 Pipeline
  • 7.6 Aphios Corporation
    • 7.6.1 Company Overview
    • 7.6.2 Pipeline

8. Early Stage Drug Discovery in Disease Segments - Strategic Consolidations

  • 8.1 R&D Licensing Agreements
    • 8.1.1 Deals by Indication
    • 8.1.2 Deals by Geography
    • 8.1.3 Deal Summaries by Therapeutic Class

9. Early Stage Drug Discovery in Disease Segments - Appendix

  • 9.1 Market Definitions
  • 9.2 Abbreviations
  • 9.3 Research Methodology
    • 9.3.1 Coverage
    • 9.3.2 Secondary Research
    • 9.3.3 Primary Research
    • 9.3.4 Expert Panel Validation
  • 9.4 Contact Us
  • 9.5 Disclaimer
  • 9.6 Sources

List of Tables:

  • Table 1: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Alzheimer's Disease, December 2010
  • Table 2: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Parkinson's Disease, December 2010
  • Table 3: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Multiple Sclerosis, December 2010
  • Table 4: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Schizophrenia, December 2010
  • Table 5: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Diabetes, December 2010
  • Table 6: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Obesity, December 2010
  • Table 7: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Rheumatoid Arthritis Therapeutics, December 2010
  • Table 8: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Crohn's Disease, December 2010
  • Table 9: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in SLE, December 2010
  • Table 10: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Allergy, December 2010
  • Table 11: Early Stage Drug Discovery in Disease Segments, Global, Patent Expiries of Major Marketed Drugs in HIV/AIDS, December 2010
  • Table 12: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in HIV/AIDS, December 2010
  • Table 13: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Hepatitis Therapeutics, December 2010
  • Table 14: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Hypertension Therapeutics, December 2010
  • Table 15: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Dyslipidemia Therapeutics, December 2010
  • Table 16: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in PAH Therapeutics, December 2010
  • Table 17: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in PAH Therapeutics (%), December 2010
  • Table 18: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Myocardial Infarction Therapeutics, December 2010
  • Table 19: Early Stage Drug Discovery in Disease Segments, Bladder Cancer Therapeutics, Prevalence by Country, 2009
  • Table 20: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Bladder Cancer Therapeutics, December 2010
  • Table 21: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in Bladder Cancer Therapeutics (%), December 2010
  • Table 22: Early Stage Drug Discovery in Disease Segments, Lung Cancer Categorized by Disease Stage, December 2010
  • Table 23: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Lung Cancer Therapeutics, December 2010
  • Table 24: Early Stage Drug Discovery in Disease Segments, Global, NSCLC Treatment by Stage of the Disease, December 2010
  • Table 25: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in NSLC Therapeutics, December 2010
  • Table 26: Early Stage Drug Discovery in Disease Segments, Breast Cancer Stage Classification, December 2010
  • Table 27: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Breast Cancer, December 2010
  • Table 28: Early Stage Drug Discovery in Disease Segments, Global, Global, Staging of Colon Cancer, December 2010
  • Table 29: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Colon Cancer Therapeutics, December 2010
  • Table 30: Early Stage Drug Discovery in Disease Segments, Global, Staging of Melanoma, December 2010
  • Table 31: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Melanoma, December 2010
  • Table 32: Early Stage Drug Discovery in Disease Segments, Global, Staging of Ovarian Cancer, December 2010
  • Table 33: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Ovarian Cancer Therapeutics, December 2010
  • Table 34: Early Stage Drug Discovery in Disease Segments, Global, Staging of Prostate Cancer, December 2010
  • Table 35: Early Stage Drug Discovery in Disease Segments, Global, Early Stage R&D Pipeline by Phase in Prostate Cancer Therapeutics, December 2010
  • Table 36: Early Stage Drug Discovery in Disease Segments, Hanall Pharmaceutical - Pipeline Products, December 2010
  • Table 37: Early Stage Drug Discovery in Disease Segments, Patrys Limited - Pipeline Products, December 2010
  • Table 38: Early Stage Drug Discovery in Disease Segments, F. Hoffmann-La Roche Ltd. - Pipeline Products, December 2010
  • Table 39: Early Stage Drug Discovery in Disease Segments, Mirna Therapeutics, Inc. - Pipeline Products, December 2010
  • Table 40: Early Stage Drug Discovery in Disease Segments, Aphios Corporation, Inc. - Pipeline Products, December 2010
  • Table 41: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by Therapeutic Class, Metabolic Disorders (%), 2005-2010
  • Table 42: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by Therapeutic Class, Immunological Disorders (%), 2005-2010
  • Table 43: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by Therapeutic Class, Cardiovascular Disorders (%), 2005-2010
  • Table 44: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by Therapeutic Class, Infections, 2005-2010
  • Table 45: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by Therapeutic Class, Oncology, 2005-2010
  • Table 46: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by Therapeutic Class, Central Nervous System Disorders, 2005-2010

List of Figures

  • Figure 1: Early Stage Drug Discovery in Disease Segments, Series of Research Activities Leading to Drug Discovery, December 2010
  • Figure 2: Early Stage Drug Discovery in Disease Segments, Stages of Drug Development, December 2010
  • Figure 3: Early Stage Drug Discovery in Disease Segments, Preclinical ADMET Studies, December 2010
  • Figure 4: Early Stage Drug Discovery in Disease Segments, Recent Technological Developments in Early Stage Development, December 2010
  • Figure 5: Early Stage Drug Discovery in Disease Segments by Therapy, December 2010
  • Figure 6: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline in Different Therapeutic Segments December 2010
  • Figure 7: Early Stage Drug Discovery in Disease Segments, Early Stage R&D pipeline in Alzheimer's Disease (%), December 2010
  • Figure 8: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Alzheimer's Disease (%), December 2010
  • Figure 9: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline in Parkinson's Disease (%), December 2010
  • Figure 10: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Parkinson's Disease (%), December 2010
  • Figure 11: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline in Multiple Sclerosis (%), December 2010
  • Figure 12: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Multiple Sclerosis (%), December 2010
  • Figure 13: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline in Schizophrenia (%), December 2010
  • Figure 14: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Schizophrenia (%), December 2010
  • Figure 15: Early Stage Drug Discovery in Disease Segments, Early Stage R&D pipeline in Diabetes (%), December 2010
  • Figure 16: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Diabetes (%), December 2010
  • Figure 17: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline in Obesity (%), December 2010
  • Figure 18: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Obesity (%), December 2010
  • Figure 19: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline in Rheumatoid Arthritis Therapeutics (%), December 2010
  • Figure 20: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Rheumatoid Arthritis (%), December 2010
  • Figure 21: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline in Crohn's Disease (%), December 2010
  • Figure 22: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Crohn's Disease (%), December 2010
  • Figure 23: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in SLE (%), December 2010
  • Figure 24: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in SLE (%), December 2010
  • Figure 25: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in Allergy(%), December 2010
  • Figure 26: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Allergy (%), December 2010
  • Figure 27: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline in HIV/AIDS Therapeutics (%), December 2010
  • Figure 28: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in HIV/AIDS (%), December 2010
  • Figure 29: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in Hepatitis Therapeutics (%), December 2010
  • Figure 30: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Hepatitis Therapeutics (%), December 2010
  • Figure 31: Early Stage Drug Discovery in Disease Segments, Early Stage R&D pipeline by Phase in Hypertension Therapeutics (%), December 2010
  • Figure 32: Early Stage Drug Discovery in Disease Segments , Early Stage R&D Pipeline by Mechanism of Action in Hypertension Therapeutics (%), December 2010
  • Figure 33: Early Stage Drug Discovery in Disease Segments , Early Stage R&D Pipeline by Phase in Dyslipidemia Therapeutics (%), December 2010
  • Figure 34: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Dyslipidemia Therapeutics (%), December 2010
  • Figure 35: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in PAH (%), December 2010
  • Figure 36: Early Stage Drug Discovery in Disease Segments , Early Stage R&D Pipeline by Phase in Myocardial Infarction (%), December 2010
  • Figure 37: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Myocardial Infarction (%), December 2010
  • Figure 38: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Bladder Cancer Therapeutics (%), December 2010
  • Figure 39: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in Lung Cancer Therapeutics (%), December 2010
  • Figure 40: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Lung Cancer Therapeutics (%), December 2010
  • Figure 41: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in NSLC Therapeutics (%), December 2010
  • Figure 42: Early Stage Drug Discovery in Disease Segments , Early Stage R&D Pipeline by Mechanism of Action in NSLC Therapeutics (%), December 2010
  • Figure 43: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in Breast Cancer Therapeutics (%), December 2010
  • Figure 44: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Breast Cancer Thereapeutics (%), December 2010
  • Figure 45: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in Colon Cancer Therapeutics (%), December 2010
  • Figure 46: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Colon Cancer Therapeutics (%), December 2010
  • Figure 47: Early Stage Drug Discovery in Disease Segments , Early Stage R&D Pipeline by Phase in Melanoma Therapeutics (%), December 2010
  • Figure 48: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Melanoma Therapeutics (%), December 2010
  • Figure 49:Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in Ovarian Cancer Therapeutics (%), December 2010
  • Figure 50: Early Stage Drug Discovery in Disease Segments , Early Stage R&D Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics(%), December 2010
  • Figure 51: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Phase in Prostate Cancer Therapeutics (%), December 2010
  • Figure 52: Early Stage Drug Discovery in Disease Segments, Early Stage R&D Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics (%), December 2010
  • Figure 53: Early Stage Drug Discovery in Disease Segments, Top Five Pharmaceutical Players in Early Stage Drug Develpment, December 2010
  • Figure 54: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by Indication (%), 2005-2010
  • Figure 55: Early Stage Drug Discovery in Disease Segments, Major Licensing Agreements by Geography (%), 2005-2010
Back to Top